ICUI
BEARISH
$125.68
Live
ICU Medical, Inc. · NASDAQ
Target $182.67
(+45.3%)
$107.0
52W Range
$160.29
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 12, 2026
Market cap
$3.14B
P/E
4189.33
ROE
0.0%
Profit margin
0.0%
Debt/Equity
0.63
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
80%
ICUI presents a stark contradiction between a strong balance sheet and a collapsing income statement. While the Piotroski F-Score of 8/9 indicates exceptional structural financial health, the company is suffering from a severe earnings crisis, evidenced by a P/E ratio of 4189.33 and a -131.5% Q/Q EPS growth. The massive disconnect between the current price ($125.68) and the Graham Number ($7.62) suggests the stock is trading at a significant premium based on future recovery hopes rather than current fundamentals. With revenue declining by 14.1% and insiders selling, the strong health score is currently insufficient to offset the operational deterioration.
Key Strengths
Strong Piotroski F-Score (8/9) indicating high structural health
Healthy Current Ratio (2.39) showing strong short-term liquidity
Manageable Debt/Equity ratio (0.63)
Strong Gross Margins (36.84%) suggesting product value remains intact
Significant positive analyst target price ($182.67) suggesting long-term recovery potential
Key Risks
Severe earnings collapse with recent Q/Q EPS growth of -131.5%
Negative revenue growth (-14.10% YoY) indicating market share loss or demand drop
Extreme valuation disconnect (Current P/E 4189.33 vs Forward P/E 13.66)
Bearish insider sentiment with consistent selling and zero buying
Poor long-term price performance (5Y Change: -38.8%)
AI Fair Value Estimate
Based on comprehensive analysis
$82.5
-34.4% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
33
Weak
15
20
40
90
0
AI Verdict
High-risk recovery play
Key drivers: Operational collapse, Strong balance sheet, Valuation bubble relative to current earnings
Confidence
85%
Value
15/100
Ref P/E 4189.33, Graham Number $7.62
Positives
- Low PEG ratio (0.08) if growth returns
Watchpoints
- P/E ratio is astronomical
- Price is vastly higher than Graham Number ($7.62)
Future
20/100
Ref Revenue Growth -14.10%
Positives
- Forward P/E (13.66) suggests expected earnings rebound
Watchpoints
- Negative YoY and Q/Q revenue growth
- Recent EPS surprise is deeply negative (-37.92% avg)
Past
40/100
Ref Historical Earnings Track Record
Positives
- Consistent history of beating estimates prior to 2025
Watchpoints
- Long-term price erosion (5Y -38.8%)
Health
90/100
Ref Piotroski F-Score 8/9
Positives
- Piotroski F-Score 8/9
- Strong Current Ratio
- Low Debt/Equity
Watchpoints
- Altman Z-Score not provided
Dividend
0/100
Ref Dividend Yield N/A
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 Dividend Strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$125.68
Analyst Target
$182.67
Upside/Downside
+45.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ICUI and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ICUI
ICU Medical, Inc.
Primary
|
-38.8% | -28.3% | -9.2% | +10.1% | -6.0% | +1.9% |
|
BEAM
Beam Therapeutics Inc.
Peer
|
-69.2% | -29.2% | +20.1% | +45.3% | +12.2% | +1.1% |
|
BKD
Brookdale Senior Living Inc.
Peer
|
+153.4% | +367.5% | +163.2% | +72.4% | +18.9% | +6.2% |
|
BLLN
BillionToOne, Inc.
Peer
|
-32.0% | -32.0% | -32.0% | -32.0% | +2.8% | +6.2% |
|
ARQT
Arcutis Biotherapeutics, Inc.
Peer
|
-30.1% | +98.3% | +53.6% | +31.6% | -14.4% | -5.2% |
ICU
ICU Medical, Inc.
Primary
5Y
-38.8%
3Y
-28.3%
1Y
-9.2%
6M
+10.1%
1M
-6.0%
1W
+1.9%
BEA
Beam Therapeutics Inc.
Peer
5Y
-69.2%
3Y
-29.2%
1Y
+20.1%
6M
+45.3%
1M
+12.2%
1W
+1.1%
BKD
Brookdale Senior Living Inc.
Peer
5Y
+153.4%
3Y
+367.5%
1Y
+163.2%
6M
+72.4%
1M
+18.9%
1W
+6.2%
BLL
BillionToOne, Inc.
Peer
5Y
-32.0%
3Y
-32.0%
1Y
-32.0%
6M
-32.0%
1M
+2.8%
1W
+6.2%
ARQ
Arcutis Biotherapeutics, Inc.
Peer
5Y
-30.1%
3Y
+98.3%
1Y
+53.6%
6M
+31.6%
1M
-14.4%
1W
-5.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
4189.33
Forward P/E
13.66
PEG Ratio
0.08
P/B Ratio
1.46
P/S Ratio
1.41
EV/Revenue
1.85
EV/EBITDA
13.35
Market Cap
$3.14B
Profitability
Profit margins and return metrics
Profit Margin
0.03%
Operating Margin
4.83%
Gross Margin
36.84%
ROE
0.04%
ROA
1.66%
Growth
Revenue and earnings growth rates
Revenue Growth
-14.1%
Earnings Growth
N/A
Q/Q Revenue Growth
-14.15%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.63
Moderate
Current Ratio
2.39
Strong
Quick Ratio
0.99
Poor
Cash/Share
$12.62
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.5B
Gross Margin
37.5%
Op. Margin
4.8%
Net Margin
-2.9%
Total Assets
$4.1B
Liabilities
$1.9B
Equity
$2.1B
Debt/Equity
0.91x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
56%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-19
$-0.64
-195.4% surprise
2025-11-06
$2.03
+41.6% surprise
2025-08-07
$2.1
+40.0% surprise
Healthcare Sector Comparison
Comparing ICUI against 264 companies in the Healthcare sector
(20 bullish, 87 neutral, 157 bearish)
P/E Ratio
4189.33
This Stock
vs
88.64
Sector Avg
+4626.5%
(Expensive)
Return on Equity (ROE)
0.04%
This Stock
vs
-46.09%
Sector Avg
-100.1%
(Below Avg)
Profit Margin
0.03%
This Stock
vs
-19.58%
Sector Avg
-100.2%
(Weaker)
Debt to Equity
0.63
This Stock
vs
4.1
Sector Avg
-84.5%
(Less Debt)
Revenue Growth
-14.1%
This Stock
vs
88.16%
Sector Avg
-116.0%
(Slower)
Current Ratio
2.39
This Stock
vs
3.58
Sector Avg
-33.3%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ICUI
ICU Medical, Inc.
|
BEARISH | $3.14B | 4189.33 | 0.0% | 0.0% | $125.68 | |
|
BEAM
Beam Therapeutics Inc.
|
BEARISH | $3.2B | - | -47.2% | -% | $31.56 | Compare |
|
BKD
Brookdale Senior Living Inc.
|
BEARISH | $3.08B | - | -212.3% | -9.9% | $12.95 | Compare |
|
BLLN
BillionToOne, Inc.
|
BEARISH | $3.41B | 569.85 | 2.3% | 1.0% | $74.08 | Compare |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
BEARISH | $2.82B | - | -9.3% | -4.3% | $22.75 | Compare |
ICUI
ICU Medical, Inc.
BEARISH
Mkt Cap
$3.1B
P/E
4189.3
ROE
0.0%
Price
$125.68
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-13 | SOUSA BEN | Chief Technology Officer | Stock Award | 1,300 | - |
| 2026-03-13 | JAIN VIVEK | Chief Executive Officer | Stock Award | 21,972 | - |
| 2026-03-13 | SANZONE VIRGINIA RUTH | General Counsel | Stock Award | 7,324 | - |
| 2026-03-13 | VOIGTLANDER CHRISTIAN B | Chief Operating Officer | Stock Award | 14,648 | - |
| 2026-03-13 | WOOLSON DANIEL | Officer | Stock Award | 2,924 | - |
| 2026-03-13 | BONNELL BRIAN MICHAEL | Chief Financial Officer | Stock Award | 14,648 | - |
| 2026-03-06 | SOUSA BEN | Chief Technology Officer | Stock Award | 9,543 | - |
| 2026-03-06 | JAIN VIVEK | Chief Executive Officer | Stock Award | 112,917 | - |
| 2026-03-06 | SANZONE VIRGINIA RUTH | General Counsel | Stock Award | 29,454 | - |
| 2026-03-06 | VOIGTLANDER CHRISTIAN B | Chief Operating Officer | Stock Award | 75,279 | - |
| 2026-03-06 | WOOLSON DANIEL | Officer | Stock Award | 19,885 | - |
| 2026-03-06 | BONNELL BRIAN MICHAEL | Chief Financial Officer | Stock Award | 75,279 | - |
| 2025-11-25 | WOOLSON DANIEL | Officer | Sale | 2,897 | $441,364 |
| 2025-11-11 | SANZONE VIRGINIA RUTH | General Counsel | Sale | 930 | $132,381 |
| 2025-11-11 | FINNEY ELISHA W | Director | Sale | 1,285 | $180,440 |
SOUSA BEN
Chief Technology Officer
2026-03-13
1,300 shares
JAIN VIVEK
Chief Executive Officer
2026-03-13
21,972 shares
SANZONE VIRGINIA RUTH
General Counsel
2026-03-13
7,324 shares
VOIGTLANDER CHRISTIAN B
Chief Operating Officer
2026-03-13
14,648 shares
WOOLSON DANIEL
Officer
2026-03-13
2,924 shares
BONNELL BRIAN MICHAEL
Chief Financial Officer
2026-03-13
14,648 shares
SOUSA BEN
Chief Technology Officer
2026-03-06
9,543 shares
JAIN VIVEK
Chief Executive Officer
2026-03-06
112,917 shares
SANZONE VIRGINIA RUTH
General Counsel
2026-03-06
29,454 shares
VOIGTLANDER CHRISTIAN B
Chief Operating Officer
2026-03-06
75,279 shares
WOOLSON DANIEL
Officer
2026-03-06
19,885 shares
BONNELL BRIAN MICHAEL
Chief Financial Officer
2026-03-06
75,279 shares
WOOLSON DANIEL
Officer
2025-11-25
2,897 shares
·
$441,364
SANZONE VIRGINIA RUTH
General Counsel
2025-11-11
930 shares
·
$132,381
FINNEY ELISHA W
Director
2025-11-11
1,285 shares
·
$180,440
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
6 analysts
Keybanc
2026-02-20
Overweight
Overweight
Piper Sandler
2026-02-20
Overweight
Overweight
Keybanc
2025-11-07
Overweight
Overweight
Piper Sandler
2025-11-07
Overweight
Overweight
Keybanc
2025-10-21
Overweight
Overweight
Past News Coverage
Recent headlines mentioning ICUI from our newsroom.
Newest → oldest
No matching news yet.